# EXELIXIS, INC. (EXEL) · Edgar & Edgarette company card

> Exelixis (EXEL) grew revenue 7.0% in FY2026 to $2.3 billion, operating margin 37.6% against a -15.8% median for biological products, (no diagnostic substances), equity 76.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 939767 · fiscal year ended 2026-01-02 · 5 audited years read · [page](https://www.pops4.com/boards/company/EXEL) · [JSON](https://www.pops4.com/boards/company/EXEL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2.3B |
| Revenue growth, 1 year | 7.0% |
| Revenue growth per year | 12.7% |
| Operating margin | 37.6% (prior year 27.9%) |
| Net margin | 33.7% |
| Operating cash flow | $884M |
| Capital spending | $8M |
| Free cash flow | $876M |
| Cash | $482M |
| Long-term debt | — |
| Total assets | $2.8B |
| Total equity | $2.2B |
| Equity ÷ assets | 76.0% |
| Return on equity | 36.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 7.69 (safe zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -2.61 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $2.3B (FY2026). Experience: revenue up 7.0% on the year, up 12.7% a year over 4 years; operating margin 37.6%, up from 27.9%. Soundness: equity 76.0% of assets, return on equity 36.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.3B and $2.7B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.1B to $2.9B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 37.6% against a -15.8% median; growth 7.0% against 21.4%.

Range logged 2026-09-29, receipt 6f2951a266ea0083, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-05-29 ([filing](https://www.sec.gov/Archives/edgar/data/939767/000093976726000074/0000939767-26-000074-index.htm))

## Recent filings

- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/939767/000093976726000116/0000939767-26-000116-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/0000939767-26-000114-index.htm)
- 8-K · filed 2026-09-11 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/939767/000093976726000108/0000939767-26-000108-index.htm)
- 8-K · filed 2026-08-31 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/939767/000093976726000104/0000939767-26-000104-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/939767/000093976726000098/0000939767-26-000098-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/0000939767-26-000096-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000939767.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=939767

## Cite

POPS4, Edgar & Edgarette: EXELIXIS, INC. (EXEL) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/EXEL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.